BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
03 September 2020 - 9:00PM
Business Wire
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or
the “Company”), a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of chronic cough
and other hypersensitization-related disorders, today announced
that Roberto Bellini, President and Chief Executive Officer of
BELLUS Health, will participate in two upcoming virtual healthcare
investor conferences.
Presentation Details: Event: Baird 2020 Global Healthcare
Conference Format: Fireside Chat Date: Thursday,
September 10, 2020 Time: 10:15 a.m. EDT
Event: H.C. Wainwright Annual Global Life Sciences
Conference Format: Corporate Presentation Date:
Monday, September 14, 2020 Time: 4:00 p.m. EDT
Replays from the Baird and H.C. Wainwright events may be
accessed on the Events and Presentations page under the Investors
& News section of BELLUS Health's website at
www.bellushealth.com. Following the events, archived webcasts and
presentations will be available on the Company’s website.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of chronic cough
and other hypersensitization-related disorders. The Company's
product candidate, BLU-5937, is being developed for the treatment
of chronic cough and chronic pruritus.
Chronic cough, the lead indication for BLU-5937, is a cough
lasting more than eight weeks and is associated with significant
adverse physical, social and psychosocial effects on health and
quality of life. It is estimated that approximately 26 million
adults in the United States suffer from chronic cough with
approximately 3 million having refractory chronic cough lasting for
more than a year and approximately 6 million having refractory
chronic cough lasting more than 8 weeks and under one year. It is
estimated that approximately 55% of patients have mild disease, and
approximately 45% have moderate to severe disease. There is no
specific therapy approved for refractory chronic cough and current
treatment options are limited.
Chronic pruritus, commonly known as chronic itch, is an
irritating sensation that leads to scratching, and persists for
longer than six weeks, which can be debilitating and has a
significant impact on quality-of-life. It is a hallmark of many
conditions, including atopic dermatitis (AD). It is estimated that
chronic pruritus associated with AD affects more than 16.9 million
adults in the United States.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200903005219/en/
Danny Matthews Director, Investor Relations and Communications
danny@bellushealth.com
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Apr 2024 to May 2024
BELLUS Health (TSX:BLU)
Historical Stock Chart
From May 2023 to May 2024